ES2676542T3 - Composiciones de CDV recombinante y usos de las mismas - Google Patents

Composiciones de CDV recombinante y usos de las mismas Download PDF

Info

Publication number
ES2676542T3
ES2676542T3 ES11707047T ES11707047T ES2676542T3 ES 2676542 T3 ES2676542 T3 ES 2676542T3 ES 11707047 T ES11707047 T ES 11707047T ES 11707047 T ES11707047 T ES 11707047T ES 2676542 T3 ES2676542 T3 ES 2676542T3
Authority
ES
Spain
Prior art keywords
alvac
polynucleotide
compositions
locus
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11707047T
Other languages
English (en)
Inventor
Jean-Christophe Audonnet
Jules Minke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Application granted granted Critical
Publication of ES2676542T3 publication Critical patent/ES2676542T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18471—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Abstract

Una composición que comprende: a) un vector de expresión del virus de la viruela del canario, en la que el vector de expresión del virus de la viruela del canario es ALVAC, en la que el vector ALVAC comprende: i) un primer polinucleótido que codifica un polipéptido de HA de CDV que tiene al menos el 80 % de identidad con la secuencia que se expone en SEQ ID NO: 2, en el que dicho primer polinucleótido se inserta en el locus C5 de ALVAC bajo el control del promotor H6 de la variolovacuna; y ii) un segundo polinucleótido que codifica un polipéptido de GM-CSF que tiene al menos el 80 % de identidad con la secuencia que se expone en SEQ ID NO: 4, en el que dicho segundo polinucleótido se inserta en el locus C3 de ALVAC y está operativamente unido al promotor H6 de la variolovacuna; y b) un vehículo farmacéutica o veterinariamente aceptable, adyuvante, diluyente o excipiente
ES11707047T 2010-02-26 2011-02-25 Composiciones de CDV recombinante y usos de las mismas Active ES2676542T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30862010P 2010-02-26 2010-02-26
PCT/US2011/026378 WO2011106743A1 (en) 2010-02-26 2011-02-25 Recombinant cdv compositions and uses thereof

Publications (1)

Publication Number Publication Date
ES2676542T3 true ES2676542T3 (es) 2018-07-20

Family

ID=44022809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11707047T Active ES2676542T3 (es) 2010-02-26 2011-02-25 Composiciones de CDV recombinante y usos de las mismas

Country Status (23)

Country Link
US (3) US20130197612A1 (es)
EP (1) EP2538972B1 (es)
JP (1) JP5898632B2 (es)
KR (1) KR20130036209A (es)
CN (1) CN102971010A (es)
AR (1) AR080313A1 (es)
AU (1) AU2011220410B9 (es)
BR (1) BR112012021545B1 (es)
CA (1) CA2791787C (es)
CY (1) CY1120430T1 (es)
DK (1) DK2538972T3 (es)
ES (1) ES2676542T3 (es)
HR (1) HRP20181188T1 (es)
HU (1) HUE039735T2 (es)
LT (1) LT2538972T (es)
NZ (1) NZ602077A (es)
PL (1) PL2538972T3 (es)
PT (1) PT2538972T (es)
RS (1) RS57759B1 (es)
RU (1) RU2567337C2 (es)
SI (1) SI2538972T1 (es)
WO (1) WO2011106743A1 (es)
ZA (1) ZA201206209B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103525776A (zh) * 2013-10-23 2014-01-22 华中农业大学 一种重组狂犬病病毒口服疫苗株及其制备方法
CN104164409A (zh) * 2014-07-18 2014-11-26 中国人民解放军军事医学科学院军事兽医研究所 含有犬gmcsf基因的重组犬瘟热病毒及其制备方法
US10081796B2 (en) * 2015-01-12 2018-09-25 International Aids Vaccine Initiative Neutralization-resistant CDV mutants and viral vectors
CN109715204B (zh) 2016-09-20 2023-08-22 勃林格殷格翰动物保健有限公司 新的ehv插入位点orf70
TW201823467A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 犬腺病毒載體
AR109540A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Moléculas promotoras para expresar antígenos virales
EP3515480A1 (en) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH New swine influenza vaccine
CN109265522B (zh) * 2018-09-29 2022-03-04 东北农业大学 用于检测犬瘟热病毒血凝蛋白h抗体的致敏聚苯乙烯纳米微球及其制备方法和应用
WO2020086939A1 (en) * 2018-10-26 2020-04-30 The Wistar Institute Of Anatomy And Biology Canine distemper vaccines and methods of treatment using the same
RU2768749C1 (ru) * 2021-06-07 2022-03-24 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Средство специфической профилактики covid-19 для плотоядных животных
CN114480441B (zh) * 2021-12-21 2023-03-21 长春维石检测技术服务有限公司 一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US702919A (en) * 1902-02-03 1902-06-24 Adam Simpson Boyd Pipe cutter and wrench.
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
JPH04502164A (ja) 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
CA2044468C (en) 1990-11-21 2006-08-22 Richard A. Nash Canine granulocyte macrophage colony stimulating factor
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
CN1117081A (zh) * 1995-03-16 1996-02-21 高云 犬瘟热狂犬病细小病毒三联活疫苗、毒种及制造方法
WO1996034109A1 (en) 1995-04-25 1996-10-31 Vical Incorporated Single-vial formulations of dna/lipid complexes
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2750865B1 (fr) * 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
AU737243B2 (en) * 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US7294338B2 (en) 1996-07-19 2007-11-13 Merial Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
CA2745736C (en) * 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
CZ299473B6 (cs) 1997-06-30 2008-08-06 Rhone-Poulenc Rorer S. A. Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
CA2375320C (en) * 1999-06-10 2013-02-19 Merial Dna vaccines for pets or for animals used in sports
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
WO2002020937A1 (en) 2000-09-06 2002-03-14 The Charles Machine Works, Inc. Auxiliary pipe loading device
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
WO2004028562A2 (de) 2002-09-23 2004-04-08 Mologen Ag Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
MXPA06000942A (es) 2003-07-24 2006-03-30 Merial Ltd Nuevas formulaciones de vacunas.
ZA200608178B (en) 2004-03-30 2008-10-29 Roussy Inst Gustave Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2008036061A2 (en) * 2005-04-06 2008-03-27 Verenium Corporation Enzymes and formulations for broad-specificity decontamination of chemical and biological warfare agents
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
WO2009124309A2 (en) * 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same

Also Published As

Publication number Publication date
US20160199483A1 (en) 2016-07-14
NZ602077A (en) 2014-08-29
JP2013521234A (ja) 2013-06-10
LT2538972T (lt) 2018-07-25
BR112012021545A2 (pt) 2018-09-04
RU2012140741A (ru) 2014-04-10
US10076566B2 (en) 2018-09-18
AU2011220410B9 (en) 2015-07-30
WO2011106743A1 (en) 2011-09-01
KR20130036209A (ko) 2013-04-11
CA2791787C (en) 2019-03-26
CA2791787A1 (en) 2011-09-01
DK2538972T3 (en) 2018-07-30
RS57759B1 (sr) 2018-12-31
CN102971010A (zh) 2013-03-13
EP2538972B1 (en) 2018-04-25
US20110236419A1 (en) 2011-09-29
AU2011220410A1 (en) 2012-09-20
HUE039735T2 (hu) 2019-01-28
SI2538972T1 (en) 2018-07-31
CY1120430T1 (el) 2019-07-10
US9327137B2 (en) 2016-05-03
RU2567337C2 (ru) 2015-11-10
HRP20181188T1 (hr) 2018-10-05
JP5898632B2 (ja) 2016-04-06
AR080313A1 (es) 2012-03-28
AU2011220410B2 (en) 2015-04-02
BR112012021545B1 (pt) 2020-11-03
ZA201206209B (en) 2013-06-26
EP2538972A1 (en) 2013-01-02
PT2538972T (pt) 2018-07-30
PL2538972T3 (pl) 2018-09-28
US20130197612A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
ES2676542T3 (es) Composiciones de CDV recombinante y usos de las mismas
ES2723273T3 (es) Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
ES2545895T3 (es) Proteína de fusión anticancerígena
PE20090483A1 (es) Vectores para la expresion multiple de genes
AR091866A1 (es) Analogos del glucagon
EA200901060A1 (ru) Новый способ и композиции
EA200870237A1 (ru) Последовательности пептидов и композиции
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
AR105822A1 (es) Análogos de insulina
CO2022013121A2 (es) Vacuna 2019-ncov (sars-cov-2)
CL2009001249A1 (es) Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia.
CL2011000947A1 (es) Polipeptido lectina; molecula de acido nucleico que la codifica; vector y celula hospedera; metodo para preparar el polipeptido; composicion farmaceutica que comprende el polipeptido; uso del polipeptido para preparar un medicamento para tratar transtorno autoinmune, inflamatorio o de piel dañada de un animal.
AR081856A1 (es) Vacuna y metodos para reducir una infeccion por campylobacter
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
PH12015500771A1 (en) Novel fc gamma receptor iib variants
PE20220429A1 (es) Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a
CL2022000161A1 (es) Vacuna contra la peste porcina africana
AR074055A1 (es) Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo
MX2021014856A (es) Vacuna de tgf-beta.
AR071696A1 (es) Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos.